Dr. Emma Stanton serves as CEO of the Pathogen Programme at the Ellison Institute for Technology in Oxford, where she leads EIT Pathogena’s mission to combat infectious diseases, address antimicrobial resistance, and prevent local outbreaks from escalating into pandemics. From 2020 to 2024, Dr. Stanton was Senior Vice President of Clinical Affairs at Oxford Nanopore Technologies and Head of Oxford Nanopore Diagnostics, responsible for bringing nanopore sequencing into global healthcare. During the COVID-19 pandemic, she played a key role as Director of Supplies, Labs, and Innovation in the UK’s NHS Test and Trace program. From 2018 to 2020, she served as CEO of Four Eyes Insight, driving clinical efficiency and healthcare improvements, following leadership roles at Beacon Health Options in the U.S. A qualified medical doctor, Dr. Stanton is a former Harkness Fellow in Healthcare Policy and Practice and holds an Executive MBA from Imperial College Business School.